glasdegib

GLASDEGIB, also known as glas deg ib, is a medication specifically designed to target proteins found in cancer cells. By inhibiting these proteins, it effectively halts the growth of cancer cells. This medication is primarily used in the treatment of acute myelogenous leukemia.

Symptoms may include muscle spasms, pain in muscles, bones or joints, excessive fatigue, nausea, vomiting, abdominal pain, constipation, and pain or sores in the mouth or throat.

DAURISMO (glasdegib) is a medication that works by inhibiting the hedgehog pathway. It contains the maleate salt of glasdegib. The chemical formula for glasdegib maleate is C25H26N6O5 and it has a molecular weight of 490.51.

Venetoclax (Venclexta) specifically acts on BCL-2, a protein found in cancer cells that promotes their prolonged survival.

Carmustine, an alkylating agent, is prescribed to treat various types of cancer such as multiple myeloma, brain tumor, Hodgkin’s disease, and non-Hodgkin’s lymphoma. Its mechanism of action involves inhibiting the growth of cancer cells, thereby slowing down or halting their progression.

Clofarabine belongs to a group of drugs known as purine nucleoside antimetabolites. Its mechanism of action involves the destruction of existing cancer cells and the inhibition of new cancer cell growth.

Decitabine belongs to a group of drugs known as hypomethylation agents. Its mechanism of action involves promoting the production of healthy blood cells in the bone marrow while also eliminating abnormal cells present in the bone marrow.

AMIFOSTINE (am i FOS teen) is a medication that serves as a protective agent. Its primary purpose is to prevent or reduce kidney damage that may occur as a result of cisplatin chemotherapy. Additionally, it is utilized to mitigate certain side effects associated with radiation therapy targeting the head or neck.

Daurismo (glasdegib) works by inhibiting the hedgehog pathway. It does this by binding to and blocking the activity of Smoothened, a protein involved in transmitting signals along the hedgehog pathway. This pathway is crucial for the development of human embryos.

Glasdegib works by blocking the sonic hedgehog receptor smoothened (SMO), which is a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. This targeting of SMO is aimed at cancerous cells, as aberrant Hh signaling is a major factor in the development of AML. Overexpression or constitutive activation of SMO is often observed in AML patients.

Please make sure to take this medication at the same time every day. Swallow the tablet whole with water and avoid breaking, crushing, or chewing it.

The initial synthesis of glasdegib (202) involved the use of (2R,4S)-1-tert-butyl 2-methyl 4-hydroxypiperidine-1,2-dicarboxylate (204) as a starting material. In this process, 204 was transformed into the mesylate, which was then substituted with sodium azide.

Azacitidine, also known as Vidaza or Onureg, is a chemotherapy drug used to treat chronic myelomonocytic leukaemia (CMML).

The rotation of the molecule within the DNA is hindered by the sugar moiety of cytarabine, leading to the cessation of DNA replication. This drug specifically targets rapidly dividing cells, like those found in cancer, during the S phase of the cell cycle.

Teniposide inhibits cell mitosis by inducing both single and double stranded DNA breaks, as well as cross linking between protein and DNA. Its mechanism of action is believed to be associated with the inhibition of type II topoisomerase activity. It is important to note that teniposide does not intercalate into DNA or bind tightly to DNA.

Venclexta works by directly binding to the BCL-2 protein, causing the displacement of other proteins like BIM. This displacement activates the process of apoptosis, ultimately resulting in programmed cell death.

These agents primarily function by competitively inhibiting ATP-binding sites in the FLT3 receptor, resulting in the halt of cell cycle progression and promotion of cell differentiation. Furthermore, the effectiveness and tolerability of different FLT3 TKIs are influenced by their varying ability to target non-FLT3 signaling pathways.

Venetoclax is the first and only BCL-2 inhibitor that aids in the restoration of apoptosis in newly diagnosed AML. The survival and proliferation of hematologic cancer cells heavily rely on the suppression of the apoptotic pathway.

The mechanism of action of Gilteritinib fumarate involves inhibiting FLT3 and AXL. It effectively suppresses FLT3 receptor signalling and cell proliferation in cells that express FLT3, such as FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y. Additionally, it triggers apoptosis in leukemic cells that express FLT3-ITD.

Clofarabine, a second generation purine nucleoside analogue, was developed to incorporate the advantageous pharmacokinetic characteristics of both fludarabine and cladribine. Its mechanism of action involves inhibiting DNA polymerases and ribonucleotide reductase, while also inducing apoptosis in both cycling and non-cycling cells.

Gemtuzumab ozogamicin is believed to work by binding specifically to cells that have the CD33 antigen. Once bound, the conjugate is taken into the cells and the calicheamicin component is released through acid hydrolysis within lysosomes.

Oral azacitidine is a type of medication known as a hypomethylating agent (HMA). It works by causing cell apoptosis, reducing the size of tumors, and improving survival rates in models of leukemia.

Glasdegib (Daurismo; Pfizer), a small-molecule Hedgehog inhibitor, was approved by the FDA on November 21, 2018. It is now used in combination with low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are 75 years or older, or who have comorbidities that prevent them from undergoing intensive induction chemotherapy.

Belonging to the category of hedgehog pathway inhibitors, Glasdegib functions by obstructing the activity of a protein that triggers the proliferation of cancerous cells.

Glasdegib, marketed as Daurismo, is a drug used to treat newly-diagnosed acute myeloid leukemia (AML) in adults over the age of 75 or those with other medical conditions that make intensive induction chemotherapy unsuitable.

The first platinum-based anti-cancer drug, cisplatin (78-0455 & 78-0450), was approved by the U.S. FDA forty years ago.

On September 21, 2022, Eli Lilly and Company’s drug, Retevmo (selpercatinib), received accelerated approval from the FDA. This approval allows for the treatment of adult patients who have locally advanced or metastatic solid tumors with a RET gene fusion. These patients must have either experienced progression on or after prior systemic treatment or have no other available treatment options.

The approval date is July 9, 1993.

On June 15, 2020, the US Food and Drug Administration (US FDA) granted accelerated approval to lurbinectedin, considering the surrogate endpoints of overall response rate and median duration of response.

On March 10, 2015, the FDA approved Unituxin (dinutuximab) for the treatment of pediatric high-risk neuroblastoma.

The FDA granted accelerated approval for nelarabine on October 28, 2005. This approval was specifically for the treatment of patients with relapsed or refractory T-ALL/T-LBL who had undergone at least two prior regimens.

Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) was approved by the Food and Drug Administration on October 24, 2023. This approval is specifically for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) who have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test.

In early December 1942, the quiet birth of chemotherapy in America was marked by the administration of 1963;105:574-8). mg/kg “Compound X” to an “x-ray resistant patient in the terminal stages of lymphosarcoma”.

Glasdegib is a hedgehog pathway inhibitor, a type of targeted therapy that disrupts the signal pathway driving cancer growth. By targeting and disrupting the Hedgehog signal, it prevents the cancer from growing.

The Food and Drug Administration (FDA) has approved vismodegib and sonidegib, two Hedgehog pathway inhibitors that target Smoothened (SMO), for the treatment of basal cell carcinoma.

The hedgehog signaling pathway is present in various animal taxa, including Drosophila and humans. It plays a crucial role in regulating embryonic development, maintaining stem cells, and impacting the development of certain cancers.

These medications function by impeding the growth of cancer cells, either by decelerating their growth or halting it altogether. They achieve this by attaching to and obstructing the activity of Smoothened, a protein located on the cell membrane that plays a role in the transmission of Hedgehog (Hh) signals. By inhibiting the Hh signaling pathway, the spread of cancer cells is impeded, potentially leading to a reduction in tumor size.

The Hh pathway is crucial for embryonic patterning and determination, and it is highly conserved. Mutations in this pathway are seen in both sporadic tumors and syndromic conditions. A common feature in these syndromes is the presence of polydactyly/syndactyly and brain overgrowth.

Drug-related toxicities are adverse effects that occur in tissues that depend on the hedgehog signaling pathway. These toxicities commonly manifest as muscle spasms, hair loss, changes in taste perception, and fluctuations in weight.

In cases where locally advanced lesions, metastatic BCC, or inoperable individuals are present, systemic treatment may be necessary. Hedgehog pathway inhibitors, such as vismodegib and sonidegib, are used as systemic treatments for BCC to inhibit the HP.

The protein known as sonic hedgehog (SHH), which is found in mammals, was given its name by a postdoctoral researcher in Cliff Tabin’s laboratory. The researcher was inspired by a comic book that his daughter was reading. SHH plays a crucial role in the hedgehog signaling pathway, which is responsible for regulating the development of bilateral animals.